Home › Entities › written_work › The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity

The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity

doctoral thesis by Kangho Suh, 2019
Place written_work Q118224948
Press Enter · cited answer in seconds

The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity

Summary

The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity is a written work[1].

Key Facts

  • The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity authored Kangho Suh[2].
  • The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity's instance of is recorded as written work[3].
  • The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity's instance of is recorded as doctoral thesis[4].
  • The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity's OCLC number is recorded as 1128028476[5].
  • The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity's language of work or name is recorded as English[6].
  • +2019-00-00T00:00:00Z marks the founding of The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity[7].
  • The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity's work available at URL is recorded as http://hdl.handle.net/1773/44669[8].
  • The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity's Handle ID is recorded as 1773/44669[9].
  • The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity's title is recorded as The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity[10].
  • The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity's thesis submitted to is recorded as University of Washington[11].
  • The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity's on focus list of Wikimedia project is recorded as WikiProject PCC Wikidata Pilot/University of Washington[12].
  • The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity's thesis committee member is recorded as Anirban Basu[13].

Body

Designation and Status

Recorded instance of include written work[3] and doctoral thesis[4].

History and Context

+2019-00-00T00:00:00Z marks the founding of The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity[7].

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

  1. [3] ↑ . wikidata.org.
  2. [4] ↑ . wikidata.org.
  3. [2] ↑ . wikidata.org.
  4. [5] ↑ . wikidata.org.
  5. [6] ↑ . Retrieved . wikidata.org.
  6. [7] ↑ . wikidata.org.
  7. [8] ↑ . wikidata.org.
  8. [9] ↑ . wikidata.org.
  9. [10] ↑ . wikidata.org.
  10. [11] ↑ . wikidata.org.
  11. [12] ↑ . wikidata.org.
  12. [13] ↑ . wikidata.org.

Class ancestry

  1. [1] ↑ . Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA 4ort.xyz Knowledge Graph. (2026). The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity. Retrieved May 3, 2026, from https://4ort.xyz/entity/the-comparative-effectiveness-safety-value-and-adherence-of-newer-p2y12-inhibitors-versus-clopidogrel-in-the-context-of-heterogeneity
MLA “The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity.” 4ort.xyz Knowledge Graph, 4ort.xyz, 3 May. 2026, https://4ort.xyz/entity/the-comparative-effectiveness-safety-value-and-adherence-of-newer-p2y12-inhibitors-versus-clopidogrel-in-the-context-of-heterogeneity.
BibTeX @misc{4ortxyz_the-comparative-effectiveness-safety-value-and-adherence-of-newer-p2y12-inhibitors-versus-clopidogrel-in-the-context-of-heterogeneity_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity}}, year = {2026}, url = {https://4ort.xyz/entity/the-comparative-effectiveness-safety-value-and-adherence-of-newer-p2y12-inhibitors-versus-clopidogrel-in-the-context-of-heterogeneity}, note = {Accessed: 2026-05-03}}
LLM prompt According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): The Comparative Effectiveness, Safety, Value, and Adherence of Newer P2Y12 Inhibitors Versus Clopidogrel in the Context of Heterogeneity — https://4ort.xyz/entity/the-comparative-effectiveness-safety-value-and-adherence-of-newer-p2y12-inhibitors-versus-clopidogrel-in-the-context-of-heterogeneity (retrieved 2026-05-03)

Canonical URL: https://4ort.xyz/entity/the-comparative-effectiveness-safety-value-and-adherence-of-newer-p2y12-inhibitors-versus-clopidogrel-in-the-context-of-heterogeneity · Last refreshed: